{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2004"],"condition":["Colorectal Cancer","Colorectal Neoplasms"],"disease":["Colorectal Cancer","Colorectal Neoplasms"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2199452"],"location":["Bulgaria"],"study_start_month":["10"],"keyword":["Capecitabine"],"repository":["ECRIN MDR"],"study_status":["Completed"],"additional_accession":[]},"is_claimable":false,"name":"A Study of Capecitabine (Xeloda) in Patients With Metastatic Colorectal Cancer","description":"This study will evaluate the efficacy, safety, and pharmacoeconomics of oral capecitabine in patients with metastatic colorectal cancer. The anticipated time on study treatment is 3-12 months, and the target sample size is 28 individuals.","dates":{"creation":"2004-10-15"},"accession":"2199452","cross_references":{"ClinicalTrials___gov":["NCT02567331"]}}